Summary
This prediction is currently active. With a performance of -8.72%, the BUY prediction for Evotec SE by Traumtanz is down slightly. This prediction currently runs until 06.07.25. The prediction end date can be changed by Traumtanz at any time. Traumtanz has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Evotec SE | -5.307% |
| iShares Core DAX® | -3.033% |
| iShares Nasdaq 100 | -3.554% |
| iShares Nikkei 225® | -3.938% |
| iShares S&P 500 | -1.517% |
According to Traumtanz what are the pros and cons of Evotec SE for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Valuable balance sheet
Innovative
Stable Large shareholder and/or long term investor
Medium risks for its business
Fair valuation
High dividend yield expected
positive Cash Flow expected
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Good culture
Some uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Top 10 in its market
Small cyclical dependencies
Future proof or reliable business model
Capable Management
Good rating
Standard Investments for future growth
Known brand
Cons
Comments by Traumtanz for this prediction
In the thread Evotec AG diskutieren
Buy mit Kursziel 10,0
